Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [<sup>177</sup>Lu]Lu-PP-F11N.

Grzmil, Michal; Imobersteg, Stefan; Blanc, Alain; Frank, Stephan; Schibli, Roger; Béhé, Martin P

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [¹⁷⁷Lu]Lu-PP-F11N.

Grzmil, Michal; Imobersteg, Stefan; Blanc, Alain; Frank, Stephan; Schibli, Roger; Béhé, Martin P.

Afiliación

Grzmil M; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Imobersteg S; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Blanc A; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Frank S; Division of Neuropathology, Institute of Pathology, University of Basel, 4031 Basel, Switzerland.
Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen, Switzerland.
Béhé MP; Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland.

Pharmaceutics ; 13(12)2021 Dec 15.

Article en En | MEDLINE | ID: mdl-34959437

Palabras clave

CCK2R; RAD001; cholecystokinin B receptor (CCKBR); everolimus; mammalian target of rapamycin complex 1 (mTORC1); minigastrin analogue PP-F11N

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Pharmaceutics Año: 2021 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google